kabutan

GNI Group Ltd.(2160) Summary

2160
TSE Growth
GNI Group Ltd.
2,352
JPY
+43
(+1.86%)
Dec 5, 11:30 am JST
15.16
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
2,353.5
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
10.8
PBR
2.61
Yield
ー%
Margin Trading Ratio
41.51
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
2,320 JPY 14.95 USD
Previous Close Dec 4
2,309 JPY 14.86 USD
High Dec 5, 9:35 am
2,379 JPY 15.33 USD
Low Dec 5, 9:00 am
2,312 JPY 14.90 USD
Volume
554,700
Trading Value
1.30B JPY 8.41M USD
VWAP
2350.2 JPY 15.16 USD
Minimum Trading Value
235,200 JPY 1,516 USD
Market Cap
0.13T JPY 0.84B USD
Number of Trades
1,695
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
3,795
1-Year High May 27, 2025
36,454
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 902,600 7,033,000 7.79
Nov 21, 2025 844,700 7,152,100 8.47
Nov 14, 2025 846,000 7,237,700 8.56
Nov 7, 2025 847,700 7,342,900 8.66
Oct 31, 2025 846,900 7,471,200 8.82
Company Profile
GNI Group Ltd. is a biotech venture company focused on drug discovery. It has research and development centers in the United States and China. The company's main product is a drug for idiopathic pulmonary fibrosis. They are also involved in genetic analysis.
Sector
Pharmaceuticals
GNI Group Ltd. operates in both the pharmaceutical and medical device sectors. In its pharmaceutical business, the company sells F351 (Etuary), a treatment for fibrosis, in the Chinese market. They also conduct research, development, manufacturing, and sales of drug compounds targeting lung diseases (interstitial lung diseases), liver diseases, and kidney diseases (chronic kidney disease). The medical device business is based in the United States and focuses on the development, manufacturing, and sales of biomaterials. The group consists of the parent company, 18 consolidated subsidiaries, and 2 affiliated companies. They also provide services such as reagents, designated manufacturing and marketing of medical devices, and domestic clinical trial management.